非马沙坦钾三水合物(Fimasartan Potassium Trihydrate) - 药物靶点：AT1R_在研适应症：高血压，原发性高血压，2型糖尿病肾脏病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Arakhor、Fimasartan、Kanarb

+ [8]

靶点

AT1R

作用方式

拮抗剂

作用机制

AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)

治疗领域

心血管疾病内分泌与代谢疾病泌尿生殖系统疾病

在研适应症

高血压原发性高血压2型糖尿病肾脏病+ [2]

非在研适应症

心肌梗塞

原研机构

Boryung Corp.

在研机构

Boryung Holdings Co., Ltd.

Boryung Corp.

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2010-09-09),

原发性高血压2型糖尿病肾脏病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C27H37KN7O4S

InChIKeyOFQQJMILOFBTRF-UHFFFAOYSA-N

CAS号1020110-23-9

关联

52

项与非马沙坦钾三水合物相关的临床试验

NCT06184269

/ Completed临床1期

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 4-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B" in Healthy Volunteers

The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1017-1" and co-administration of "BR1017-1A" and "BR1017-1B" in healthy volunteers

开始日期2023-12-23

申办/合作机构

Boryung Corp.

NCT05930028

/ Completed临床3期

A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension patients with primary hypercholesterolemia

开始日期2023-07-13

申办/合作机构

Boryung Corp.

NCT05372380

/ Completed临床1期

An Open Label, One-sequence, 3-period Study to Evaluate Drug-drug Interactions and Safety Between "BR1017-1" and "BR1017-2" in Healthy Volunteers

To evaluate the influence of BR1017-1 and BR1017-2 on pharmacokinetics and safety when administered separately or co-administered to healthy volunteers.

开始日期2022-05-09

申办/合作机构

Boryung Corp.

100 项与非马沙坦钾三水合物相关的临床结果

登录后查看更多信息

100 项与非马沙坦钾三水合物相关的转化医学

登录后查看更多信息

100 项与非马沙坦钾三水合物相关的专利（医药）

登录后查看更多信息

166

项与非马沙坦钾三水合物相关的文献（医药）

2024-11-01·EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Novel Fimasartan Fluidized Solid Dispersion and Its Tablet: Preparation, Crystallinity, Solubility, Dissolution, and Pharmacokinetics in Beagle Dogs

Article

作者: Choi, Han-Gon ; Shin, Dong Chul ; Jin, Sung Giu ; Cho, Jung Hyun ; Ud Din, Fakhar

BACKGROUND AND OBJECTIVES:

Fimasartan, an angiotensin II receptor antagonist, exhibits low bioavailability due to its poor solubility; consequently, using solubilization technologies is essential to improve its bioavailability. In this study, novel fimasartan fluidized solid dispersion (FFSD) was developed using a fluid bed granulator to enhance the drug solubility and oral bioavailability.

METHODS:

An appropriate FFSD was prepared in 50% ethanol using a fluid bed granulator, and its drug dissolution, morphology, and crystallinity were evaluated in comparison to the powdered drug. Moreover, the dissolution in various pH conditions and pharmacokinetics of the FFSD tablet in beagle dogs were investigated compared to the commercial fimasartan tablet.

RESULTS:

Among the hydrophilic polymers tested, hydroxypropyl methylcellulose (HPMC) showed the highest solubility. The FFSD, composed of fimasartan, HPMC, and microcrystalline cellulose at the weight ratio of 20:10:25, gave a granular aggregation of several particles with a smooth surface. The drug in this FFSD existed as an amorphous state, leading to a greatly increased drug dissolution. The FFSD tablet was prepared by compressing a mixture of FFSD, mannitol, croscarmellose sodium, and magnesium stearate at the weight ratio of 55:40:5:1. The FFSD tablet gave significantly higher drug dissolution, plasma concentrations, maximum plasma concentration (C_max) and area under the whole blood concentration-time curve (AUC) values than did the commercial fimasartan tablet. In the beagle dogs, the FFSD tablet (140.39 ± 27.40 ng·h/ml) had about a 1.7-fold higher AUC than the commercial fimasartan tablet (80.58 ± 22.18 ng·h/ml), indicating an enhancement in the bioavailability.

CONCLUSIONS:

This novel FFSD tablet could be a potential oral pharmaceutical product with the improved oral bioavailability of fimasartan.

2024-09-01·Analytical and Bioanalytical Chemistry

In situ metabolomic analysis of osteonecrosis of the femoral head (ONFH) using MALDI MSI

Article

作者: Zhang, Yinguang ; Li, Jiantao ; Nie, Honggang ; Han, Yehua ; Li, Chen ; Wang, Yinghao ; Di, Shuangshuang ; Jia, Lan ; Sheng, Yiqi ; Liu, Jikun

Osteonecrosis of the femoral head (ONFH) is a common orthopedic disease characterized by disability and deformity. To better understand ONFH at molecular level and to explore the possibility of early diagnosis, instead of diagnosis based on macroscopic spatial characteristics, a matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) method was developed for ONFH disease for the first time. The most challenging step for ONFH MSI is to deal with human bone tissues which are much harder than the other biological samples studied by the reported MSI studies. In this work, the MSI sectioning method of hard bone tissues was established using tender acids and a series of test criteria. Small-molecule metabolites, such as lipids and amino acids, were detected in bone sections, realizing the in situ detection of spatial distribution of biometabolites. By comparing the distribution of metabolites from different regions of normal femoral head, ONFH bone tissue (ONBT), and adjacent ONFH bone tissue (ANBT), the whole process of femoral head from normal stage to necrosis was monitored and visualized at molecular level. Moreover, this developed MSI method was used for metabolomics study of ONFH. 72 differential metabolites were identified, suggesting that disturbances in energy metabolism and lipid metabolism affected the normal life activities of osteoblasts and osteoclasts. This study provides new perspectives for future pathological studies of ONFH.

2024-09-01·HYPERTENSION RESEARCH

Risk of pneumonia-related hospitalization after initiating angiotensin-converting enzyme inhibitors compared with angiotensin II receptor blockers: a retrospective cohort study using LIFE Study data

Article

作者: Uemura, Ryosuke ; Maeda, Megumi ; Murata, Fumiko ; Fukuda, Haruhisa ; Hieda, Michinari

There is insufficient evidence that angiotensin-converting enzyme inhibitors (ACEIs) can reduce pneumonia by inducing a dry cough that confers a protective effect on the airway. To increase the evidence base on the clinical use of ACEIs for pneumonia prevention, this retrospective cohort study aimed to comparatively examine the risk of pneumonia-related hospitalization between ACEI initiators and angiotensin II receptor blocker (ARB) initiators using claims data from two Japanese municipalities. We identified persons who were newly prescribed any ACEI or ARB as their first antihypertensive agent between April 2016 and March 2020. The Fine-Gray method was applied to a Cox proportional hazards model to estimate the subdistribution hazard ratio (HR) of ACEI use (reference: ARB use) for pneumonia-related hospitalization, with death treated as a competing risk. Sex, age, comorbidities, medications, and pneumococcal immunization were included as covariates. The analysis was conducted on 1421 ACEI initiators and 9040 ARB initiators, and the adjusted subdistribution HR of ACEI use was estimated to be 1.21 (95% confidence interval: 0.89-1.65; P = 0.22). ACEI initiation did not demonstrate any significant preventive effect against pneumonia-related hospitalization relative to ARB initiation. There remains a lack of strong evidence on the protective effects of ACEIs, and further research is needed to ascertain the benefits of their use in preventing pneumonia. We conducted a large-scale retrospective cohort study using real-world healthcare data from a Japanese population. In this study, ACEI initiation did not indicate a significant preventive effect against pneumonia-related hospitalization.

2

项与非马沙坦钾三水合物相关的新闻（医药）

2023-12-08

·SYNAPSE

What are HMG-CoA reductase inhibitors and how do you quickly get the latest development progress?

HMG-CoA reductase is an enzyme that plays a crucial role in the human body's cholesterol synthesis pathway. It is responsible for catalyzing the conversion of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) to mevalonate, a key precursor in the production of cholesterol. By regulating the activity of HMG-CoA reductase, the body can control the amount of cholesterol synthesized. This enzyme is the target of statin drugs, which inhibit its activity, leading to a reduction in cholesterol levels. Maintaining proper HMG-CoA reductase function is essential for maintaining cholesterol homeostasis and preventing the development of cardiovascular diseases. HMG-CoA reductase inhibitors, also known as statins, are a class of drugs used to lower cholesterol levels in the body. The first statin, lovastatin, was approved by the FDA in 1987. Since then, several other statins have been developed, including atorvastatin, simvastatin, and rosuvastatin. Statins work by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. By reducing cholesterol levels, statins can help prevent heart attacks, strokes, and other cardiovascular diseases. In addition to their cholesterol-lowering effects, statins have been shown to have other beneficial effects, such as reducing inflammation and improving endothelial function. They have also been investigated for their potential to treat other conditions, such as Alzheimer’s disease, multiple sclerosis, and certain types of cancer. The future of HMG-CoA reductase inhibitors looks promising, with ongoing research into new statins and other cholesterol-lowering drugs. Researchers are also investigating the potential of statins to treat other diseases, such as osteoporosis and autoimmune disorders. However, there are also concerns about the long-term effects of statin use, such as an increased risk of diabetes and liver damage. As such, further research is needed to fully understand the benefits and risks of these drugs. The mechanism of action of HMG-CoA reductase inhibitorsHMG-CoA reductase inhibitors are a class of drugs commonly known as statins. From a biomedical perspective, these drugs are used to lower cholesterol levels in the blood. They work by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in the production of cholesterol in the liver. By blocking this enzyme, statins reduce the amount of cholesterol synthesized in the body, leading to a decrease in LDL (low-density lipoprotein) cholesterol, often referred to as "bad" cholesterol. Lowering LDL cholesterol levels can help prevent the development of cardiovascular diseases such as heart attacks and strokes. Additionally, statins may have other beneficial effects, such as reducing inflammation and improving the function of blood vessels. HMG-CoA reductase inhibitors are commonly prescribed to individuals with high cholesterol levels or those at risk of cardiovascular diseases. Catalog of HMG-CoA reductase InhibitorsThe currently marketed HMG-CoA reductase inhibitors include: Ezetimibe/Pitavastatin CalciumAtorvastatin/FimasartanFenofibrate/Pitavastatin CalciumAmlodipine Besylate/Fimasartan Potassium Trihydrate/Rosuvastatin CalciumAmlodipine Besylate/Olmesartan Medoxomil/Rosuvastatin CalciumAtorvastatin Calcium Hydrate/Metformin HydrochlorideAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilPitavastatin MagnesiumAmlodipine/Losartan Potassium/Rosuvastatin CalciumValsartan/Rosuvastatin CalciumFor more information, please click on the image below. What is the purpose of using HMG-CoA reductase inhibitors?HMG-CoA reductase inhibitors, are used to lower cholesterol levels in the body. They are used adjunctively with diet and exercise to treat and manage hypercholesterolemia (high cholesterol in blood) and for primary and secondary prevention of coronary heart disease. For more information, please click on the image below to log in and search. How can I get the most recent advancements in HMG-CoA reductase inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of HMG-CoA reductase inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

2022-06-15

·PRNewswire

Antihypertensive Drugs Market is Estimated to Rise at a CAGR of 3% during the Forecast Period, observes TMR Study

The global antihypertensive drugs market is likely to be driven by the introduction of novel drug/therapeutic compounds with disease-modifying capabilities and better effectiveness North America's considerable market share is due to high uptake of antihypertensive medications in the US and an increasing number of new drug approvals by the US FDA ALBANY, N.Y., June 15, 2022 /PRNewswire/ -- The revenue of antihypertensive drugs market stood at US$ 30.2 Bn in 2021. The global market is likely to develop at a CAGR of 3% during the forecast period, from 2022 to 2031. The global antihypertensive drugs market is likely to attain a valuation of US$ 40 Bn by 2031. The global antihypertensive drugs market is anticipated to be propelled by a rise in the launch of novel pharmaceuticals and diagnostic agents. Besides, major industrial advancements such as partnerships and set-up of R&D facilities are also expected to fuel antihypertensive drugs market expansion. The global market is expected to be driven by rising disposable income as well as the introduction of innovative disease-modifying treatments during the forecast period. Firms in the antihypertensive drugs industry are projected to benefit from significant expansion in telemedicine and e-Health applications in the long run. In order to meet treatment objectives, most hypertension patients need a mix of antihypertensive medications. In an effort to boost efficacy of the first drug, combination therapy involves adding some other family of blood pressure medication to it. There is a significant unmet need for antihypertensive medications, indicating a shortage of viable products. This creates a huge opportunity for new market entrants to profit from unmet demands, owing to patient non-compliance or poor compliance with already existing medicines. Antihypertensive drug trends in stroke patients could reveal critical insights into secondary prevention gaps that are likely to help guide future treatments. In order to acquire a competitive advantage over other market participants, healthcare businesses are strengthening R&D in the fields of resistant hypertension therapy and genomics. Request Brochure of Antihypertensive Drugs Market Research Report – Key Findings of Market Report Innovative antihypertensive medications and pharmacological treatments, which successfully target illness progression, are predicted to have promising benefits. Novel medicines for disorders such as calcium channel blockers (CCB), angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) are projected to transform the existing picture in the global antihypertensive pharmaceuticals market. The market is projected to be driven by the introduction of new products that are more safe and more efficient. A few of such medications under development are diuretic azilsartan/amlodipine/hydrochlorothiazide (phase III) by Takeda Pharmaceuticals and fimasartan/amlodipine (phase III) by Boryung Pharmaceutical. The primary hypertension category is expected to lead the global market in the forthcoming years. Over the last decade, hypertension has gradually become a major public health issue. Salt consumption among children in developed countries is often higher than the recommended amount. In developing countries, a similar tendency prevails, which is likely to act as the largest opportunity for antihypertensive drugs. In the initial years of life, a positive sodium balance is required for development. Nevertheless, excessive salt consumption might have negative cardiovascular implications, which is expected to result in driving market demand for antihypertensive drugs Request for Analysis of COVID-19 Impact on Antihypertensive Drugs Market – Global Antihypertensive Drugs Market: Growth Drivers Based on medication, the combination therapy category is expected to lead the market with a significant percentage in terms of revenue. This is one of the key market segments in antihypertensive drugs. This segment is being driven by an increase in the geriatric population suffering from comorbid illnesses like congenital heart disease and an emphasis on combination medications. As a result, companies are ramping up the manufacturing of combination antihypertensive medications to suit the demands of senior individuals with many medical conditions. In 2021, the hospital pharmacies category led the global market by distribution channel. Hospital pharmacies often have a wide selection of pharmaceuticals on reserve, including specialist and experimental drugs. In order to diversify their revenue streams, hospital pharmacists are extending the supply of hypertension management devices. Get Exclusive PDF Sample Copy of Antihypertensive Drugs Market Report – Global Antihypertensive Drugs Market: Key Players Some of the key market players are Pfizer, Inc. Takeda Pharmaceutical Company Limited Boehringer Ingelheim GmbH Daiichi Sankyo Company, Limited F. Hoffmann-La Roche Ltd. Sanofi S.A. Make an Enquiry Before Buying – Global Antihypertensive Drugs Market: Segmentation Therapy Type Diuretics Angiotensin Converting Enzyme Inhibitors Angiotensin Receptor Blockers Beta-blockers Vasodilators Calcium Channel Blockers Renin Inhibitors Alpha-blockers Others Type Primary Hypertension Secondary Hypertension Medication Type Monotherapy Combination Therapy Fixed Dose Combinations Distribution Channel Retail Pharmacies Hospital Pharmacies Online Pharmacies Others Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Healthcare Industry Reports by Transparency Market Research: Erectile Dysfunction Drugs Market: Increase in use of such drugs to treat the above mentioned disease conditions will continue to encourage the use of erectile dysfunction drugs, thereby driving the erectile dysfunction drugs market. Point-of-Care Diagnostics Market: Increase in incidence of diabetes, cancer, and other chronic diseases, and technological advancements in the field of point-of-care that has resulted in new and innovative products are projected to drive the global point-of-care diagnostics market during the forecast period. Rapid Medical Diagnostic Kits Market: Widespread availability, aging population, and shift in technological & commercial environment are projected to drive the global rapid medical diagnostics kits market during the forecast period. In Vitro Diagnostics Market: Rise in health care expenditure due to increase in awareness about various health care programs and availability of cost-effective diagnostic methods are likely to augment the global in vitro diagnostics market. Pressure Ulcer Diagnostics Market: Rise in awareness about pressure ulcer diagnostic tools & tests, and surge in COVID-19 patients suffering from pressure ulcers & other chronic diseases are anticipated to boost the growth of the global pressure ulcer diagnostics market during the forecast period. Lyme Disease Diagnostics Market: The surge in the frequency and prevalence of Lyme disease and rising investments from government organizations and large corporates for developing diagnostic kits are primary reasons contributing to the growth of the global Lyme disease diagnostics market. Hemostasis Diagnostics Market: Rise in prevalence of blood clotting disorders, high prevalence of cardiovascular diseases are projected to drive the global hemostasis diagnostics market during the forecast period. Meningitis Diagnostic Testing Market: The EMEA meningitis diagnostic testing market is expected to reach the value of US$ 83.51 Mn by the end of 2031 and to expand at a CAGR of 3.7% from 2021 to 2031. Rapid diagnostic tests are significantly changing the EMEA meningitis diagnostic testing market. About Us Transparency Market Research (TMR) is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Us: Rohit Bhisey Transparency Market Research Inc. Corporate Headquarter Downtown 1000 N. West Street Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] Logo: SOURCE Transparency Market Research

诊断试剂

100 项与非马沙坦钾三水合物相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	非马沙坦钾三水合物	C09CA10	DB09279

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高血压	墨西哥	Boryung Holdings Co., Ltd.	2014-09-15
原发性高血压	韩国	Boryung Corp.	2010-09-09
2型糖尿病肾脏病	韩国	Boryung Corp.	2010-09-09

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床3期	美国	Boryung Corp.	2016-02-11
肾脏疾病	临床3期	韩国	Boryung Holdings Co., Ltd.	2015-11-24
原发性高胆固醇血症	临床1期	美国	Boryung Corp.	2023-12-23
血脂障碍	临床阶段不明	韩国	Boryung Holdings Co., Ltd.	2020-03-21
糖尿病肾病	临床前	韩国	Boryung Holdings Co., Ltd.	-
心肌梗塞	临床前	韩国	Boryung Holdings Co., Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02620306 (FANTASTIC, Pubmed) 人工标引	临床3期	非糖尿病慢性肾脏病	341	Fimasartan	窪簾積餘簾蓋範糧觸願(範築構顧願憲積範壓壓) = 構顧遞鏇鏇遞壓壓獵夢衊壓淵夢顧壓製艱網觸 (衊簾憲獵遞網窪鹽鬱鹹 )	优效	2022-09-20
				Losartan	窪簾積餘簾蓋範糧觸願(範築構顧願憲積範壓壓) = 顧廠鏇網選糧鹽蓋窪膚衊壓淵夢顧壓製艱網觸 (衊簾憲獵遞網窪鹽鬱鹹 )
NCT02495324 (FAST, Pubmed) 人工标引	临床4期	原发性高血压	312	Fimasartan	蓋製膚襯艱積積憲餘艱(窪範窪蓋膚鬱膚廠範築) = 願餘艱遞餘願選積糧顧獵鹹鑰構繭網齋糧鑰壓 (夢築衊淵製願構顧鏇觸, 15.07) 更多	积极	2020-01-23
				Valsartan	蓋製膚襯艱積積憲餘艱(窪範窪蓋膚鬱膚廠範築) = 範齋壓膚醖醖蓋壓窪餘獵鹹鑰構繭網齋糧鑰壓 (夢築衊淵製願構顧鏇觸, 13.87) 更多
NCT02248961 (CTgov)	临床3期	高血压	179	Fimasartan (Kanarb (Fimasartan))	膚遞鹽糧觸夢選膚獵鹽(觸鏇鏇齋衊鹽糧積鏇鹽) = 願繭壓窪鹽鬱齋遞廠壓顧鬱網襯積獵觸構願顧 (繭遞艱夢膚鹽遞夢鹽艱, 5.9) 更多	-	2019-05-06
				Losartan (Cozaar® (Losartan))	膚遞鹽糧觸夢選膚獵鹽(觸鏇鏇齋衊鹽糧積鏇鹽) = 齋鬱獵願鹽淵憲築醖糧顧鬱網襯積獵觸構願顧 (繭遞艱夢膚鹽遞夢鹽艱, 5.9) 更多
ESH2018	N/A	-	-	Angiotensin II	鏇衊壓積觸鹽獵壓繭憲(蓋餘築憲範網鹹齋衊構) = 齋膚窪艱艱夢鏇鬱獵獵壓繭遞齋鬱獵廠廠餘鹹 (衊襯觸鏇窪築齋淵壓襯 ) 更多	-	2018-06-01
				Fimasartan	憲夢淵積構積廠夢顧壓(憲鹽衊觸製壓選製鏇鏇) = 繭遞繭壓醖獵遞醖構憲獵蓋積鹹齋醖壓衊選製 (夢鏇餘蓋鬱繭窪壓壓糧 ) 更多
ESH2018	N/A	-	312	Fimasartan	襯壓築襯膚獵觸築網膚(淵簾襯繭憲製齋餘夢願) = 醖夢膚夢鑰衊遞壓繭簾糧鹽鹽鬱選鹹獵鹽鹽遞 (鹹蓋願鹹簾選醖艱顧廠 ) 更多	积极	2018-06-01
				Valsartan	襯壓築襯膚獵觸築網膚(淵簾襯繭憲製齋餘夢願) = 襯窪築繭壓淵窪艱鏇鑰糧鹽鹽鬱選鹹獵鹽鹽遞 (鹹蓋願鹹簾選醖艱顧廠 ) 更多
NCT00922480 (CTgov)	临床3期	原发性高血压	506	Losartan (Control: Losartan / Week 12 -ITT)	範製遞膚遞製齋簾觸衊(獵觸餘構築艱壓遞鑰夢) = 鹹願觸遞膚醖艱壓選壓艱鬱廠遞鏇壓獵範網鬱 (膚餘鬱鬱觸醖廠積窪構, 7.72)	-	2018-02-13
				Fimasartan (Test: Fimasartan / Week 12 -ITT)	範製遞膚遞製齋簾觸衊(獵觸餘構築艱壓遞鑰夢) = 醖齋膚網範鬱醖觸鏇壓艱鬱廠遞鏇壓獵範網鬱 (膚餘鬱鬱觸醖廠積窪構, 7.53)
NCT00922441 (CTgov)	临床2期	原发性高血压	92	Fimasartan 60 mg group (Fimasartan 1)	糧鹽遞獵夢醖淵艱構窪(網醖網廠鹽夢鑰襯鏇餘) = 蓋膚網壓鬱鏇積簾積顧顧願廠襯艱淵膚齋淵鏇 (蓋壓鹽蓋獵憲鹽廠廠憲, 鏇鏇網遞膚顧衊選襯鹽 ~ 衊鬱簾繭觸齋壓齋鏇夢) 更多	-	2018-02-13
				Fimasartan 120 mg group (Fimasartan 2)	糧鹽遞獵夢醖淵艱構窪(網醖網廠鹽夢鑰襯鏇餘) = 簾顧範窪繭窪衊鏇鏇衊顧願廠襯艱淵膚齋淵鏇 (蓋壓鹽蓋獵憲鹽廠廠憲, 衊糧鏇願網積餘蓋鏇鬱 ~ 獵艱構顧積遞鹹簾鹹醖) 更多
NCT01878201 (Pubmed \| Korean J Intern Med) 人工标引	临床2期	高血压	75	fimasartan	遞願餘窪鑰淵鬱鏇壓鹹(範艱網鬱觸夢廠鏇餘齋) = 築醖製窪膚餘膚範簾憲鹹艱齋夢獵繭簾網網壓 (網簾醖齋繭製衊壓糧淵, 11.9) 更多	积极	2017-11-01
				valsartan	遞願餘窪鑰淵鬱鏇壓鹹(範艱網鬱觸夢廠鏇餘齋) = 衊艱夢積鬱襯窪襯遞膚鹹艱齋夢獵繭簾網網壓 (網簾醖齋繭製衊壓糧淵, 11.6) 更多
WSC2017	N/A	-	-	Fimasartan 0.6mg/kg	鬱淵願糧艱淵醖膚膚獵(鹹膚網鹹網窪範窪壓廠) = 糧餘襯餘窪積窪願觸顧糧齋餘構壓鹽遞鬱築齋 (網積糧範顧蓋簾膚遞艱 ) 更多	-	2017-10-07
				Fimasartan 1.2mg/kg	鬱淵願糧艱淵醖膚膚獵(鹹膚網鹹網窪範窪壓廠) = 膚顧簾選鹹夢窪選壓淵糧齋餘構壓鹽遞鬱築齋 (網積糧範顧蓋簾膚遞艱 ) 更多
NCT02466490 (Pubmed) 人工标引	临床3期	原发性高血压	272	fimasartan	襯醖選遞構鹹餘鏇鏇醖(鑰膚顧齋觸憲鏇網鑰齋) = 顧繭淵夢齋膚獵鏇構積夢顧壓範顧鏇蓋獵鏇襯 (衊遞憲憲繭夢齋鏇鏇膚, 14.1) 更多	积极	2017-10-01